Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib in HER2-Altered Biliary Tract Cancers
NCT04571710Phase 2Withdrawn
- Sponsor
- Hengrui
- Start
- Nov 2020
- Primary completion
- Jun 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib in biliary tract cancer (BTC), sponsored by Hengrui. Primary endpoint: Objective Response Rate at 2 years. Planned start Nov 2020; status: withdrawn.
02
Drugs
pyrotinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04571710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04571710.